A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.

doi:10.1038/s41467-020-15318-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.

Nature communications - 25 Mar 2020

Kong Li Ren, Mohamed Salleh Nur Afiqah Binte, Ong Richard Weijie, Tan Tuan Zea, Syn Nicholas L, Goh Robby Miguel, Fhu Chee Wai, Tan Daniel S W, Iyer N Gopalakrishna, Kannan Srinivasaraghavan, Verma Chandra S, Lim Yaw Chyn, Soo Ross, Ho Jingshan, Huang Yiqing, Lim Joline S J, Yan Benedict Junrong, Nga Min En, Lim Seng Gee, Koeffler H Phillip, Lee Soo Chin, Kappei Dennis, Hung Huynh The, Goh Boon Cher

Abstract excerpt

c-MET receptors are activated in cancers through genomic events like tyrosine kinase domain mutations, juxtamembrane splicing mutation and amplified copy numbers, which can be inhibited by c-MET small molecule inhibitors. Here, we discover that the most common polymorphism known to affect MET gene (N375S), involving the semaphorin domain, confers exquisite binding affinity for HER2 and enables METN375S to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Head and Neck Neoplasms

Share to Protein Interaction Domains and Motifs

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Receptor, ErbB-2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32214092
DOI: 10.1038/s41467-020-15318-5
PMCID: PMC7096530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.PMID 32214092Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

Meta-analysis of functional expression and mutational analysis of c-Met in various cancers.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

MET in human cancer: germline and somatic mutationsSemantic proximity Read ↗

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Semantic proximity Read ↗

Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2Semantic proximity Read ↗

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domainSemantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.Semantic proximity Read ↗

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.Semantic proximity Read ↗

MET receptor sequence variants R970C and T992I lack transforming capacity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.